Humanetics, Mount Sinai Sign Agreement
Humanetics Corp., Minneapolis, MN, has signed an exclusive license agreement with Mount Sinai School of Medicine, Manhattan, NY, to further develop and commercialize an oral agent, referenced as NIC5-15, to combat Alz­heimer’s disease. This compound has been shown in pre-clinical studies and animal models to be effective in preventing the formulation of beta amyloid plaques, which are believed to be a cause of Alzheimer’s disease. Humanetics has also entered into a clinical research agreement with investigators at Mount Sinai to test the effect of the compound in humans.